Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
Corren J., Castro M., O'Riordan T., Hanania NA., Pavord ID., Quirce S., Chipps BE., Wenzel SE., Thangavelu K., Rice MS., Harel S., Jagerschmidt A., Khan AH., Kamat S., Maroni J., Rowe P., Lu Y., Amin N., Pirozzi G., Ruddy M., Graham NMH., Teper A.
<h4>Background</h4>Dupilumab blocks the shared receptor component for IL-4 and IL-13, key drivers of type 2 inflammation, including IgE-mediated allergic inflammation in asthma. In the LIBERTY ASTHMA QUEST (NCT02414854) study, dupilumab reduced severe asthma exacerbations and improved forced expiratory volume in 1 second (FEV<sub>1</sub>) in patients with uncontrolled, moderate-to-severe asthma with greater efficacy observed in patients with elevated type 2 inflammatory biomarkers (blood eosinophils and fractional exhaled nitric oxide) at baseline.<h4>Objective</h4>We assessed dupilumab's effect on key asthma outcomes in QUEST patients with/without evidence of allergic asthma (total serum IgE ≥30 IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35 kU/L at baseline).<h4>Methods</h4>Severe exacerbation rates and change from baseline in FEV<sub>1</sub>, asthma control, and markers of type 2 inflammation during the 52-week treatment period were assessed.<h4>Results</h4>In the allergic asthma subgroup (n = 1083), dupilumab 200/300 mg every 2 weeks versus placebo reduced severe asthma exacerbation rates (-36.9%/-45.5%; both P < .01), improved FEV<sub>1</sub> at week 12 (0.13 L/0.16 L; both P < .001; improvements were evident by the first evaluation at week 2) with greater efficacy observed in patients with elevated type 2 inflammatory biomarkers at baseline, and improved asthma control. Dupilumab treatment also resulted in rapid and sustained reductions in type 2 inflammatory biomarkers. Comparable results were observed in patients without evidence of allergic asthma (n = 819).<h4>Conclusion</h4>Dupilumab reduced severe exacerbation rates, improved FEV<sub>1</sub> and asthma control, and suppressed type 2 inflammatory biomarkers in patients with uncontrolled, moderate-to-severe asthma with or without evidence of allergic asthma, highlighting the key role of IL-4 and IL-13 in airway inflammation.